RxDoctor Payments DataLook up a doctor →

Samuel Kieley, MD

Urology · Woodbury, MNNPI 1003058546

Payments from drug & device makers

$5,767in general payments, 2019–2025

Across 234 payments — averaging $24.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$514
  • Myriad Genetic Laboratories, Inc.$488
  • AbbVie$446
  • Dendreon Pharmaceuticals LLC$395
  • Teleflex LLC$358
  • Johnson & Johnson$347
  • plus $3K from 38 others

What the payments were for

  • Food & beverage$5,767100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,767 in reported general payments places this provider in the 80th percentile of 247 urology providers in Minnesota.

See all urology providers in Minnesota

Medicare billing

Part B allowed, 2024
$1,195,784
Medicare patients
2,091
Services billed
67,382

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide73$1,086,717
MyrbetriqMirabegron223$145,883
OrgovyxRelugolix26$61,811
GemtesaVibegron54$34,521
Tamsulosin Hcl1,217$23,847
Abiraterone Acetate29$18,445
Methenamine Hippurate212$14,295
Finasteride635$10,232
Mirabegron ErMirabegron12$5,237
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst92$4,496
Testosterone21$3,899
Oxybutynin Chloride ErOxybutynin Chloride188$3,733
Trimethoprim54$2,800
Potassium Citrate ErPotassium Citrate15$2,195
Dutasteride19$1,653

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$295$1,232,600296 claims
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$294$96,33280 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 247 urology providers in Minnesota.

Other urology in Woodbury

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →